PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Vortioxetine and Tranylcypromine Interaction

Drug interaction information between Vortioxetine and Tranylcypromine.

Vortioxetine and Tranylcypromine have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Vortioxetine and Tranylcypromine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.

Drug A

Vortioxetine

Serotonin Modulator

Drug B

Tranylcypromine

Monoamine Oxidase Inhibitor (MAOI)

How They Interact

These medications both raise serotonin levels in your body. Combining them can lead to a serious reaction known as serotonin syndrome.

What To Do

This combination should be avoided. Talk to your doctor about the safe amount of time to wait when switching between these medications.

FDA Label Information

[see Dosage and Administration (2.4) , Contraindications (4) , Warnings and Precautions (5.2) ] Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact Concomitant use of TRINTELLIX with other serotonergic drugs increases the risk of serotonin syndrome.

Vortioxetine Also Interacts With

View all Vortioxetine interactions →

Frequently Asked Questions

Can I take Vortioxetine and Tranylcypromine together?

This is a moderate interaction. This combination should be avoided. Talk to your doctor about the safe amount of time to wait when switching between these medications.

How serious is the interaction between Vortioxetine and Tranylcypromine?

This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.

Why do Vortioxetine and Tranylcypromine interact?

These medications both raise serotonin levels in your body. Combining them can lead to a serious reaction known as serotonin syndrome.

Understanding the Vortioxetine and Tranylcypromine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Vortioxetine belongs to the Serotonin Modulator class and Tranylcypromine belongs to the Monoamine Oxidase Inhibitor (MAOI) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These medications both raise serotonin levels in your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Vortioxetine has 18 total documented interactions on file in this dataset, and Tranylcypromine has 42. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: This combination should be avoided. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Vortioxetine or Tranylcypromine based on a web page, speak with your prescriber or pharmacist before making any change.

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.